Google NewsRhythm Biosciences (ASX:RHY) Shares Climb 14%: Here's What Investors Are Watching - Kalkine
Rhythm Biosciences (ASX:RHY) Shares Climb 14%: Here's What Investors Are Watching Kalkine
RHYTHM BIOSCIENCES ORDINARY (RHY) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
StockheadRhythm Biosciences doubles ColoSTAT cancer test network to 78 centres
ColoSTAT Access Program now has ten participating clinician sites across Australia. ... Read More The post Rhythm Biosciences doubles ColoSTAT cancer test network to 78 centres appeared first on Stockhead.
First geneType Clinical Test Sale in South East Asia
other announcement
Pitt Street flags upside as Rhythm delivers on long-held ‘dream’
Series of significant milestones achieved in past 12 months as company starts to look overseas for growth. ... Read More The post Pitt Street flags upside as Rhythm delivers on long-held ‘dream’ appeared first on Stockhead.
Rhythm ramps up ColoSTAT rollout as 4Cyte sites come online
Rhythm activates collection centres with 4Cyte Pathology for blood-based ColoSTAT colorectal cancer test ... Read More The post Rhythm ramps up ColoSTAT rollout as 4Cyte sites come online appeared first on Stockhead.
RHY Executes SE Asian Genetype Distribution Agreement
other announcement
Exercise of RHYO Options underwritten for $4.5m to $6.0m
other announcement
Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
other announcement
ColoSTAT commercial deployment - First physician enrolled
other announcement
Rhythm Biosciences secures strategic alliance with AGRF
other announcement
Rhythm Biosciences secures commercial alliance with CancerIQ
other announcement
Landmark Publication Validates ColoSTAT Clinical Performance
other announcement
Launch of new Genetype CRC risk Test with ColoSTAT synergy
other announcement